Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StatinMigEpisodic
2022-502176-23-00Phase 2Withdrawn
- Sponsor
- St. Olavs University Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of atorvastatin in migraine (3 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Change in number of migraine days per 4 weeks (atorvastatin 40 mg vs placebo). Planned start Mar 2023; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
migraine
Beyond the preview
Go deeper on 2022-502176-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502176-23-00.